![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Immunicon (MM) | NASDAQ:IMMC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.19 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 18, 2008
IMMUNICON CORPORATION
(Exact Name of Registrant Specified in Charter)
Delaware | 000-50677 | 23-2269490 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
3401 Masons Mill Road, Suite 100 Huntingdon Valley, Pennsylvania |
19006 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (215) 830-0777
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions ( see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 3.01. | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On April 24, 2008, Immunicon Corporation (Immunicon) issued a press release announcing that on April 18, 2008, it received notification (the Notice) from The NASDAQ Stock Market (NASDAQ) indicating that trading in Immunicons common stock will be suspended and Immunicons common stock will be delisted from The NASDAQ Capital Market at the opening of business on April 29, 2008 (the Delisting Date), unless Immunicon appeals NASDAQs determination.
As previously disclosed in the Form 8-K filed by Immunicon on April 4, 2008, Immunicon had received notice from NASDAQ on April 2, 2008, indicating that Immunicon was not in compliance with Marketplace Rule 4310(c)(3) (the Rule) because Immunicon failed to have the minimum of $2,500,000 in stockholders equity required for continued listing on The NASDAQ Capital Market. Immunicon was provided until April 17, 2008 to submit a specific plan to achieve and sustain compliance with all applicable continued listing requirements of The NASDAQ Capital Market, including the Rule. On April 18, 2008, Immunicon notified NASDAQ that it would not submit such a plan but rather would pursue quotation of its common stock on the Over-the-Counter Bulletin Board (OTCBB).
As such, Immunicon does not intend to appeal NASDAQs determination of the Delisting Date and is in the process of transferring the quotation of its common stock to OTCBB. In that regard, Immunicon has been advised that a market maker has filed the necessary application with the Financial Industry Regulatory Authority to make a market in Immunicons common stock on OTCBB. It is Immunicons expectation that its common stock will be eligible for quotation on OTCBB on the Delisting Date.
A copy of Immunicons press release announcing receipt of the Notice is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
99.1 Press release
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNICON CORPORATION | ||
By: |
BYRON D. HEWETT |
|
Byron D. Hewett | ||
President and Chief Executive Officer |
Dated: April 24, 2008
EXHIBIT INDEX
Exhibit No. |
Document |
|
99.1 | Press release |
1 Year Immunicon Chart |
1 Month Immunicon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions